Alterity Therapeutics Secures Significant Funding
Alterity Therapeutics (NASDAQ: ATHE), a leading biotechnology firm committed to developing innovative therapies for neurodegenerative diseases, has successfully engaged in a capital raising effort amounting to A$20.0 million. This move underscores the company's dedication to advancing its clinical initiatives, particularly for its promising treatment, ATH434.
Details of the Strategic Placement
The capital raising was achieved through binding commitments for fully paid ordinary shares, also known as "New Shares," targeted at both international and local professional investors. The shares were offered at A$0.012 each, representing a discounted rate relative to previous market prices. Interestingly, there were no options included in this transaction, allowing stakeholders to fully experience the benefits of their investment in Alterity.
Positive Investor Sentiment
David Stamler, M.D., CEO of Alterity, expressed gratitude for the strong support from the investment community, particularly noting the enthusiastic response following the favorable results from their Phase 2 clinical trial for Multiple System Atrophy. With the approval process in sight, the company aims to utilize these funds effectively to navigate regulatory pathways.
Advancing ATH434 Development
Part of the funding will be allocated to ongoing clinical development and regulatory activities essential for the progression of ATH434. The company recently reported positive topline results from its Phase 2 clinical trials for ATH434, demonstrating its potential to offer meaningful benefits while maintaining a favorable safety profile. With these developments, Alterity is keen to engage with the FDA regarding future steps in the ATH434 development journey.
Utilization of Proceeds from the Placement
The proceeds from this strategic placement will bolster Alterity's financial position, allowing the company to cover several critical areas, including non-clinical studies and chemical manufacturing controls. Strong funding will enable the organization to continue its important work in developing therapies that could significantly alter the trajectory for patients suffering from neurodegenerative diseases.
About Alterity Therapeutics
Alterity Therapeutics is a clinical-stage biotechnology company focused on creating breakthroughs in the treatment of neurodegenerative disorders. The organization is particularly committed to providing innovative therapies for conditions like Parkinson's disease and Multiple System Atrophy. With their flagship product, ATH434, they have shown promising results in clinical trials, pointing towards a bright future for both the company and its potential beneficiaries.
Contact Information
For further inquiries, investors and interested parties can reach out to Alterity Therapeutics:
Australia Contact:
Ana Luiza Harrop
Email: we-aualteritytherapeutics@we-worldwide.com
Phone: +61 452 510 255
U.S. Contact:
Remy Bernarda
Email: remy.bernarda@iradvisory.com
Phone: +1 (415) 203-6386
Frequently Asked Questions
What is the purpose of the A$20 million capital raising?
The capital raised will be used to support Alterity's clinical programs and regulatory strategies for ATH434, a treatment for neurodegenerative diseases.
How much was the discount on the shares offered?
The shares were offered at a 7.7% discount to the last closing price prior to the placement.
What clinical trials has Alterity conducted?
Alterity has recently reported positive results from its Phase 2 clinical trials for ATH434, focusing on Multiple System Atrophy.
Who is the CEO of Alterity Therapeutics?
The CEO of Alterity Therapeutics is David Stamler, M.D.
How can investors contact Alterity Therapeutics?
Investors can contact Alterity through their provided email and phone numbers, depending on their region (Australia or U.S.).
